CLAIMS

1. Use of a mesenchymal stem cell exosome in the preparation of a medicament for promoting, restoring or enhancing cell adhesion homeostasis in an individual suffering from dystrophic epidermolysis bullosa (EB).

2. Use according to Claim 1, in which the homeostasis comprises maintenance of a cell adhesion response.

3. Use according to Claim 1 or 2, in which a therapeutically effective amount of exosome is to be administered to the individual.

4. Use according to any preceding claim, in which the exosome comprises at least one biological property of a mesenchymal stem cell such as a biological activity of a mesenchymal stem cell conditioned medium (MSC-CM).

5. Use according to Claim 4, in which the biological activity comprises cardioprotection.

6. Use according to any preceding claim, in which the exosome is capable of reducing infarct size for example as assayed in a mouse or pig model of myocardial ischemia and reperfusion injury, or which is capable of reducing oxidative stress for example as assayed in an in vitro assay of hydrogen peroxide (H_2O_2)-induced cell death.

7. Use according to any preceding claim, in which the exosome has a size of between 50 nm and 100 nm as determined by electron microscopy.

8. Use of a mesenchymal stem cell exosome in the preparation of a medicament for the treatment or prevention of a disease characterised by an alteration of cell adhesion homeostasis, in which the disease consists of dystrophic epidermolysis bullosa (EB).